FDA approves first-of-its-kind flu vaccine for adults over 50

• The U.S. Food and Drug Administration (FDA) approved Moderna's "mFLUSIVA," the first mRNA-based flu vaccine, for individuals over 50.
• This approval is a significant step towards modernizing flu vaccine development, enabling faster manufacturing to address various strains.
• Robert F. Kennedy Jr. previously withdrew $500 million in funding for mRNA vaccine development, claiming the vaccines were ineffective against Covid and flu, a stance contradicted by scientific studies.
• The FDA initially declined to review Moderna's application due to concerns about insufficient testing but later reversed its decision after Moderna submitted a revised application.
• The medical community criticized Kennedy's funding cut, warning of potential costs in both finances and lives, given that the flu continues to be a substantial public health concern.

IN FULL

First mRNA-based flu shot approved in US - despite RFK Jr’s objections to the science